For the past few years, FDA has attempted to re-approve all the old drugs that made it to market before the current regulatory framework was in place. In an effort to catch up, the Wall Street Journal says, the regulatory body has been offering three years of market exclusivity to any company willing to do the clinical work and affirm the older drugs' efficacy.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.